Selected publications
-
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Blood advances.
2019
Academic Article
GET IT
Times cited: 3 -
Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: Phase 1 results and long-term follow-up.
Blood.
2018
Academic Article
GET IT
Times cited: 21 -
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.
Leukemia.
2018
Academic Article
GET IT
Times cited: 45 -
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
Blood.
2017
Academic Article
GET IT
Times cited: 48 -
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.
Blood.
2017
Conference Paper
GET IT
Times cited: 51 -
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: Interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
The Lancet Oncology.
2017
Academic Article
GET IT
Times cited: 91 -
The european hematology association roadmap for european hematology research: A consensus document.
Haematologica.
2016
Academic Article
GET IT
Times cited: 28 -
Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: Final results from a pivotal study.
Haematologica.
2015
Information Resource
GET IT
Times cited: 16 -
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.
Journal of Clinical Oncology.
2012
Academic Article
GET IT
Times cited: 199 -
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse.
Blood.
2009
Academic Article
GET IT
Times cited: 37